Blog

A new study shows that, for a small number of lucky individuals, it is possible to have a faulty gene that causes severe disease and not get that disease (think cystic fibrosis, etc). The problem though is that researchers don’t

From the Telegraph: “Researchers from Orlando Health in Florida detected a biomarker released by the brain during injury. They found that the biomarker can stay in the bloodstream for up to a week – which means patients who suffer delayed

Here it is — the $1000 whole genome. Veritas Genetics is co-founded by Harvard Medical School professor and genetics pioneer Dr. George Church. The company first broke the $1,000 genome barrier in 2015 when it made whole genome sequencing available

Here’s a neat idea reported on by The Scientist. “Five years ago, scientists at the Memorial Sloan Kettering Cancer Center in New York City showed that circulating tumor cells (CTCs) could both colonize new metastases and travel back to their

The idea behind the company is to expel toxic, worn-out cells called “senescent cells.” Here’s the story in Fortune.

From STAT NEWS: The long-running Framingham Heart Study has found that “the rate of dementia was 3.6 percent in the late 1970s and early 1980s, falling to 2.8 percent a decade later, 2.2 percent a decade after that, and 2

The Economist has a good story on the progress being made in cryobanking. Read the story here.

Remember the horrific Thalidomide disaster when babies were being born without limbs? Well, turns out the drug might have a happier purpose. Researchers have figured out how to use it to bioengineer a way to kill cancer. Here’s the story.

From TechCrunch: “From Google[x]’s cancer-seeking nanopills to Atomwise, a machine-learning platform working on finding the cure to orphan diseases, the Bay Area offers several startups and organizations coming at the problem in a different way.Incubators such as Y Combinator, IndieBio

Here’s the story in Forbes: “What if a simple blood test could detect any cancer early, when it was still easy to treat? It sounds like science fiction. But Illumina ILMN -0.61%, the $24 billion (market cap) biotechnology company that